ROVI announces the agreement with Sandoz to distribute and market its Enoxaparin biosimilar


No votes yet
 
Related
ROVI holds its 2021 General Shareholders Meeting
Laboratorios Farmaceuticos Rovi, SA has held its today General Ordinary Shareholders Meeting, in which a valuation of the 2020 financial...
6 min
17/06/2021
During their visit to the facilities, they have been accompanied by the CEO of ROVI, Juan López-Belmonte; the vice president and CFO,...
2 min
14/05/2021